| Name | Title | Contact Details |
|---|
CipherHealth is an award-winning and proven technology solutions partner committed to enhancing communication and care throughout the patient journey. Since 2009, CipherHealth has helped shape the patient engagement category, delivering groundbreaking products to help care providers effectively and efficiently deliver quality care for their patients. CipherHealth`s suite of patient engagement programs sets new standards for care and empowers healthcare organizations to create purposeful conversations to ensure the best possible outcomes for staff members, patients, and their loved ones.
As one of the world`s premier cancer centers, Memorial Sloan Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and superb educational programs. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available today as we work to discover more effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and the biomedical research agenda around the world.
EnovateIT is a Canton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovative Living Inc is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.